Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
PCSA
$2.004
$
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Next Earnings
2026-02-25
Beta
1.023
Average Volume
Market Cap
Last Dividend
CIK
0001533743
ISIN
US74275C4033
CUSIP
74275C403
CEO
George K. Ng
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
10
IPO Date
2014-03-07
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference | VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer, and Patrick Lin, Chief Business & Strategy Officer and Founder, will attend the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California. | GlobeNewsWire | 2026-01-12 09:15:00 |
| Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study | Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today reported that it completed the enrollment and dosing of the 20 patients required for the planned formal interim analysis in its ongoing Phase 2 clinical study evaluating NGC-Cap, Processa's proprietary combination treatment of PCS6422 and capecitabine, in patients with advanced or metastatic breast cancer. | GlobeNewsWire | 2026-01-05 09:15:00 |
| PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study | Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer. | Zacks Investment Research | 2025-12-18 10:26:11 |
| Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data? | Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) stock is skyrocketing on Wednesday, with a session volume of 2.73 million compared to the average volume of 389.09 thousand, as per data from Benzinga Pro. | Benzinga | 2025-12-17 13:10:08 |
| Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer | Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine | GlobeNewsWire | 2025-12-17 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13D/A | 2026-02-23 | 2026-02-23 | View Filing |
| 8-K | 2026-02-19 | 2026-02-19 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 4 | 2026-02-04 | 2026-02-04 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| 8-K | 2025-12-15 | 2025-12-15 | View Filing |
| SC 13G/A | 2025-11-07 | 2025-11-07 | View Filing |
| 10-Q | 2025-11-06 | 2025-11-06 | View Filing |
| SC 13D/A | 2025-10-15 | 2025-10-15 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| 4 | 2025-10-03 | 2025-10-03 | View Filing |
| S-8 | 2025-09-22 | 2025-09-22 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 4/A | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K/A | 2025-09-16 | 2025-09-16 | View Filing |
| 8-K | 2025-09-12 | 2025-09-11 | View Filing |
| 8-K | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-09-02 | 2025-09-02 | View Filing |
| DEFA14A | 2025-08-25 | 2025-08-25 | View Filing |
| 8-K | 2025-08-25 | 2025-08-25 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13D | 2025-08-13 | 2025-08-13 | View Filing |
| DEF 14A | 2025-08-13 | 2025-08-13 | View Filing |
| SC 13G/A | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-08 | 2025-08-08 | View Filing |
| PRER14A | 2025-08-08 | 2025-08-08 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| PRE 14A | 2025-07-31 | 2025-07-31 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 4 | 2025-07-28 | 2025-07-28 | View Filing |
| 8-K | 2025-07-25 | 2025-07-25 | View Filing |
| 424B5 | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-18 | 2025-07-18 | View Filing |
| 8-K | 2025-07-15 | 2025-07-15 | View Filing |
| 8-K | 2025-07-01 | 2025-07-01 | View Filing |
| 8-K | 2025-06-30 | 2025-06-30 | View Filing |
| SC 13G | 2025-06-24 | 2025-06-24 | View Filing |
| SC 13G | 2025-06-23 | 2025-06-23 | View Filing |
| SC 13G | 2025-06-23 | 2025-06-23 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| 424B4 | 2025-06-18 | 2025-06-18 | View Filing |
| EFFECT | 2025-06-18 | 2025-06-18 | View Filing |
| 8-K | 2025-06-17 | 2025-06-17 | View Filing |
| S-1 | 2025-06-13 | 2025-06-13 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| DEF 14A | 2025-05-12 | 2025-05-12 | View Filing |
| DEFA14A | 2025-05-12 | 2025-05-12 | View Filing |
| 10-Q | 2025-05-08 | 2025-05-08 | View Filing |
| PRE 14A | 2025-05-01 | 2025-05-01 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 4 | 2025-04-11 | 2025-04-11 | View Filing |
| 10-K | 2025-03-20 | 2025-03-20 | View Filing |
| 4/A | 2025-02-18 | 2025-02-18 | View Filing |
| 4/A | 2025-02-18 | 2025-02-18 | View Filing |
| 4/A | 2025-02-18 | 2025-02-18 | View Filing |
| 4/A | 2025-02-18 | 2025-02-18 | View Filing |
| 8-K | 2025-02-11 | 2025-02-11 | View Filing |
| 8-K | 2025-02-10 | 2025-02-10 | View Filing |
| 4 | 2025-01-31 | 2025-01-31 | View Filing |
| 8-K | 2025-01-30 | 2025-01-30 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
| 4 | 2025-01-29 | 2025-01-29 | View Filing |
| 424B4 | 2025-01-29 | 2025-01-29 | View Filing |
| EFFECT | 2025-01-28 | 2025-01-28 | View Filing |
| S-1/A | 2025-01-27 | 2025-01-27 | View Filing |
| S-1/A | 2025-01-16 | 2025-01-16 | View Filing |
| S-1 | 2024-12-20 | 2024-12-20 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Fibonacci | 74.42% | 1.59 | 3 | 1.05 | 0.66 | 49.63 |
| Heikin Ashi Strategy | 74.29% | 1.24 | 8 | 0.89 | 0.53 | 49.49 |
| Adaptive Wave | 73.03% | 2 | 3 | 0.81 | 0.59 | 48.24 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | x | xxx | xxxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxxx | xxxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxx | x |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |